Adalimumab Biosimilar Market is expected to reach US$ 2.85 Bn. at a CAGR of 17.6% during the forecast period 2029.To know about the Research Methodology :- Request Free Sample Report The report study has analyzed the revenue impact of the COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.
Adalimumab Biosimilar Market Dynamics
Biosimilar is also called as subsequent entry biologics or follow-on biologics. Adalimumab is a medicine used to treat psoriatic arthritis, rheumatoid arthritis, and various other diseases. Adalimumab biosimilar is equally effective and safe in reducing inflammation as Humira. The global market for adalimumab biosimilar is expected to grow the market from 2022 to 2029 thanks to growing incidence of arthritis among the worldwide population. The major trend in the market is high investment in the manufacturing and research of the new adalimumab biosimilars. However, the global adalimumab biosimilar market is hampered by the shortage of skillful specialists to operate. Also, the factor like the high sensitivity towards temperature, absence of efficacy and safety, high manufacturing cost related to generic drugs are expected to limit the market growth during the 2022-2029. By distribution channel, the retail pharmacy is expected to grow at the highest xx% CAGR during forecast period because of the rapidly increasing adoption of retail pharmacy portals to buy the drugs. Similarly, the report covers the segments in the adalimumab biosimilar market such as product, and distribution channel.Adalimumab Biosimilar Market Regional Insights
Region-wise, North America is expected to hold the largest market share of the adalimumab biosimilars market during the forecast period, thanks to the increasing occurrence of rheumatoid arthritis with the rise in the aged population. However, Europe is the second-largest market, because of a rise in the approvals of the new biosimilars, a rise in the aged population, high investment in the research and manufacturing of the new adalimumab biosimilars. From 2018, five new adalimumab biosimilars names as ABP501 (Amgevita), SB5 (Imraldi), GP2017 (Hyrimoz), FKB327 (Hulio), MSB11022 (Idacio) have been permitted in Europe. ABP501 was the first European Commission permitted adalimumab biosimilar. It is sold by Amgen under the brand name AMGEVITA. These new biosimilars are expected to drive the growth of the global adalimumab biosimilars market in the forecast period. Companies are involved in adopting sustainable strategies to gain competitive edges such as new product launch, product up gradation and collaborative agreements. For example, in Oct 2018, Amgen Company launched AMGEVITA a biosimilar of adalimumab. The objective of the report is to present a comprehensive analysis of the Global Adalimumab Biosimilar Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Adalimumab Biosimilar Market dynamics, structure by analyzing the market segments and projects the Global Adalimumab Biosimilar Market size. Clear representation of competitive analysis of key players By Product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Adalimumab Biosimilar Market make the report investor’s guide.Adalimumab Biosimilar Market Scope: Inquire before buying
Adalimumab Biosimilar Market, by Product
• Exemptia • Adalirel • Cipleumab • OthersAdalimumab Biosimilar Market, by Distribution Channel
• Hospitals Pharmacies • Retail Pharmacies • OthersAdalimumab Biosimilar Market, by Region
• North America • Europe • Asia Pacific • Middle East & Africa • South AmericaAdalimumab Biosimilar Market Key Players
• Alfred E. Tiefenbacher (GmbH & Co. KG) • Amgen Inc. • Boehringer Ingelheim International GmbH • Glenmark • Zydus Cadila • Torrent Pharmaceuticals Ltd. • Reliance Life Sciences • Emcure Pharmaceuticals Ltd • Cipla Inc. • Hetero Frequently Asked Questions: 1. Which region has the largest share in Adalimumab Biosimilar Market? Ans: North America region holds the highest share in 2021. 2. What is the growth rate of Adalimumab Biosimilar Market? Ans: The Adalimumab Biosimilar Market is growing at a CAGR of 17.6% during forecasting period 2022-2029. 3. What is scope of the Adalimumab Biosimilar market report? Ans: Adalimumab Biosimilar Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Adalimumab Biosimilar market? Ans: The important key players in the Adalimumab Biosimilar Market are – Alfred E. Tiefenbacher, Amgen Inc., Boehringer Ingelheim International GmbH, Glenmark, Zydus Cadila, Torrent Pharmaceuticals Ltd., Reliance Life Sciences, Emcure Pharmaceuticals Ltd, Cipla Inc., and Hetero. 5. What is the study period of this market? Ans: The Adalimumab Biosimilar Market is studied from 2021 to 2029.
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Adalimumab Biosimilar Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Adalimumab Biosimilar Market Analysis and Forecast 6.1. Adalimumab Biosimilar Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Adalimumab Biosimilar Market Analysis and Forecast, By Product 7.1. Introduction and Definition 7.2. Key Findings 7.3. Adalimumab Biosimilar Market Value Share Analysis, By Product 7.4. Adalimumab Biosimilar Market Size (US$ Mn) Forecast, By Product 7.5. Adalimumab Biosimilar Market Analysis, By Product 7.6. Adalimumab Biosimilar Market Attractiveness Analysis, By Product 8. Global Adalimumab Biosimilar Market Analysis and Forecast, By Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Adalimumab Biosimilar Market Value Share Analysis, By Distribution Channel 8.4. Adalimumab Biosimilar Market Size (US$ Mn) Forecast, By Distribution Channel 8.5. Adalimumab Biosimilar Market Analysis, By Distribution Channel 8.6. Adalimumab Biosimilar Market Attractiveness Analysis, By Distribution Channel 9. Global Adalimumab Biosimilar Market Analysis, by Region 9.1. Adalimumab Biosimilar Market Value Share Analysis, by Region 9.2. Adalimumab Biosimilar Market Size (US$ Mn) Forecast, by Region 9.3. Adalimumab Biosimilar Market Attractiveness Analysis, by Region 10. North America Adalimumab Biosimilar Market Analysis 10.1. Key Findings 10.2. North America Adalimumab Biosimilar Market Overview 10.3. North America Adalimumab Biosimilar Market Value Share Analysis, By Product 10.4. North America Adalimumab Biosimilar Market Forecast, By Product 10.4.1. Exemptia 10.4.2. Adalirel 10.4.3. Cipleumab 10.4.4. Others 10.5. North America Adalimumab Biosimilar Market Value Share Analysis, By Distribution Channel 10.6. North America Adalimumab Biosimilar Market Forecast, By Distribution Channel 10.6.1. Hospitals Pharmacies 10.6.2. Retail Pharmacies 10.6.3. Others 10.7. North America Adalimumab Biosimilar Market Value Share Analysis, by Country 10.8. North America Adalimumab Biosimilar Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Adalimumab Biosimilar Market Analysis, by Country 10.10. U.S. Adalimumab Biosimilar Market Forecast, By Product 10.10.1. Exemptia 10.10.2. Adalirel 10.10.3. Cipleumab 10.10.4. Others 10.11. U.S. Adalimumab Biosimilar Market Forecast, By Distribution Channel 10.11.1. Hospitals Pharmacies 10.11.2. Retail Pharmacies 10.11.3. Others 10.12. Canada Adalimumab Biosimilar Market Forecast, By Product 10.12.1. Exemptia 10.12.2. Adalirel 10.12.3. Cipleumab 10.12.4. Others 10.13. Canada Adalimumab Biosimilar Market Forecast, By Distribution Channel 10.13.1. Hospitals Pharmacies 10.13.2. Retail Pharmacies 10.13.3. Others 10.14. North America Adalimumab Biosimilar Market Attractiveness Analysis 10.14.1. By Product 10.14.2. By Distribution Channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Adalimumab Biosimilar Market Analysis 11.1. Key Findings 11.2. Europe Adalimumab Biosimilar Market Overview 11.3. Europe Adalimumab Biosimilar Market Value Share Analysis, By Product 11.4. Europe Adalimumab Biosimilar Market Forecast, By Product 11.4.1. Exemptia 11.4.2. Adalirel 11.4.3. Cipleumab 11.4.4. Others 11.5. Europe Adalimumab Biosimilar Market Value Share Analysis, By Distribution Channel 11.6. Europe Adalimumab Biosimilar Market Forecast, By Distribution Channel 11.6.1. Hospitals Pharmacies 11.6.2. Retail Pharmacies 11.6.3. Others 11.7. Europe Adalimumab Biosimilar Market Value Share Analysis, by Country 11.8. Europe Adalimumab Biosimilar Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Norway 11.8.7. Russia 11.9. Europe Adalimumab Biosimilar Market Analysis, by Country 11.10. Germany Adalimumab Biosimilar Market Forecast, By Product 11.10.1. Exemptia 11.10.2. Adalirel 11.10.3. Cipleumab 11.10.4. Others 11.11. Germany Adalimumab Biosimilar Market Forecast, By Distribution Channel 11.11.1. Hospitals Pharmacies 11.11.2. Retail Pharmacies 11.11.3. Others 11.12. U.K. Adalimumab Biosimilar Market Forecast, By Product 11.12.1. Exemptia 11.12.2. Adalirel 11.12.3. Cipleumab 11.12.4. Others 11.13. U.K. Adalimumab Biosimilar Market Forecast, By Distribution Channel 11.13.1. Hospitals Pharmacies 11.13.2. Retail Pharmacies 11.13.3. Others 11.14. France Adalimumab Biosimilar Market Forecast, By Product 11.14.1. Exemptia 11.14.2. Adalirel 11.14.3. Cipleumab 11.14.4. Others 11.15. France Adalimumab Biosimilar Market Forecast, By Distribution Channel 11.15.1. Hospitals Pharmacies 11.15.2. Retail Pharmacies 11.15.3. Others 11.16. Italy Adalimumab Biosimilar Market Forecast, By Product 11.16.1. Exemptia 11.16.2. Adalirel 11.16.3. Cipleumab 11.16.4. Others 11.17. Italy Adalimumab Biosimilar Market Forecast, By Distribution Channel 11.17.1. Hospitals Pharmacies 11.17.2. Retail Pharmacies 11.17.3. Others 11.18. Spain Adalimumab Biosimilar Market Forecast, By Product 11.18.1. Exemptia 11.18.2. Adalirel 11.18.3. Cipleumab 11.18.4. Others 11.19. Spain Adalimumab Biosimilar Market Forecast, By Distribution Channel 11.19.1. Hospitals Pharmacies 11.19.2. Retail Pharmacies 11.19.3. Others 11.20. Norway Adalimumab Biosimilar Market Forecast, By Product 11.20.1. Exemptia 11.20.2. Adalirel 11.20.3. Cipleumab 11.20.4. Others 11.21. Norway Adalimumab Biosimilar Market Forecast, By Distribution Channel 11.21.1. Hospitals Pharmacies 11.21.2. Retail Pharmacies 11.21.3. Others 11.22. Russia Adalimumab Biosimilar Market Forecast, By Product 11.22.1. Exemptia 11.22.2. Adalirel 11.22.3. Cipleumab 11.22.4. Others 11.23. Russia Adalimumab Biosimilar Market Forecast, By Distribution Channel 11.23.1. Hospitals Pharmacies 11.23.2. Retail Pharmacies 11.23.3. Others 11.24. Europe Adalimumab Biosimilar Market Attractiveness Analysis 11.24.1. By Product 11.24.2. By Distribution Channel 11.25. PEST Analysis 11.26. Key Trends 11.27. Key Developments 12. Asia Pacific Adalimumab Biosimilar Market Analysis 12.1. Key Findings 12.2. Asia Pacific Adalimumab Biosimilar Market Overview 12.3. Asia Pacific Adalimumab Biosimilar Market Value Share Analysis, By Product 12.4. Asia Pacific Adalimumab Biosimilar Market Forecast, By Product 12.4.1. Exemptia 12.4.2. Adalirel 12.4.3. Cipleumab 12.4.4. Others 12.5. Asia Pacific Adalimumab Biosimilar Market Value Share Analysis, By Distribution Channel 12.6. Asia Pacific Adalimumab Biosimilar Market Forecast, By Distribution Channel 12.6.1. Hospitals Pharmacies 12.6.2. Retail Pharmacies 12.6.3. Others 12.7. Asia Pacific Adalimumab Biosimilar Market Value Share Analysis, by Country 12.8. Asia Pacific Adalimumab Biosimilar Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. Malaysia 12.8.7. Indonesia 12.9. Asia Pacific Adalimumab Biosimilar Market Analysis, by Country 12.10. China Adalimumab Biosimilar Market Forecast, By Product 12.10.1. Exemptia 12.10.2. Adalirel 12.10.3. Cipleumab 12.10.4. Others 12.11. China Adalimumab Biosimilar Market Forecast, By Distribution Channel 12.11.1. Hospitals Pharmacies 12.11.2. Retail Pharmacies 12.11.3. Others 12.12. India Adalimumab Biosimilar Market Forecast, By Product 12.12.1. Exemptia 12.12.2. Adalirel 12.12.3. Cipleumab 12.12.4. Others 12.13. India Adalimumab Biosimilar Market Forecast, By Distribution Channel 12.13.1. Hospitals Pharmacies 12.13.2. Retail Pharmacies 12.13.3. Others 12.14. Japan Adalimumab Biosimilar Market Forecast, By Product 12.14.1. Exemptia 12.14.2. Adalirel 12.14.3. Cipleumab 12.14.4. Others 12.15. Japan Adalimumab Biosimilar Market Forecast, By Distribution Channel 12.15.1. Hospitals Pharmacies 12.15.2. Retail Pharmacies 12.15.3. Others 12.16. South Korea Adalimumab Biosimilar Market Forecast, By Product 12.16.1. Exemptia 12.16.2. Adalirel 12.16.3. Cipleumab 12.16.4. Others 12.17. South Korea Adalimumab Biosimilar Market Forecast, By Distribution Channel 12.17.1. Hospitals Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Others 12.18. Australia Adalimumab Biosimilar Market Forecast, By Product 12.18.1. Exemptia 12.18.2. Adalirel 12.18.3. Cipleumab 12.18.4. Others 12.19. Australia Adalimumab Biosimilar Market Forecast, By Distribution Channel 12.19.1. Hospitals Pharmacies 12.19.2. Retail Pharmacies 12.19.3. Others 12.20. Malaysia Adalimumab Biosimilar Market Forecast, By Product 12.20.1. Exemptia 12.20.2. Adalirel 12.20.3. Cipleumab 12.20.4. Others 12.21. Malaysia Adalimumab Biosimilar Market Forecast, By Distribution Channel 12.21.1. Hospitals Pharmacies 12.21.2. Retail Pharmacies 12.21.3. Others 12.22. Indonesia Adalimumab Biosimilar Market Forecast, By Product 12.22.1. Exemptia 12.22.2. Adalirel 12.22.3. Cipleumab 12.22.4. Others 12.23. Indonesia Adalimumab Biosimilar Market Forecast, By Distribution Channel 12.23.1. Hospitals Pharmacies 12.23.2. Retail Pharmacies 12.23.3. Others 12.24. Vietnam Adalimumab Biosimilar Market Forecast, By Product 12.24.1. Exemptia 12.24.2. Adalirel 12.24.3. Cipleumab 12.24.4. Others 12.25. Vietnam Adalimumab Biosimilar Market Forecast, By Distribution Channel 12.25.1. Hospitals Pharmacies 12.25.2. Retail Pharmacies 12.25.3. Others 12.26. Asia Pacific Adalimumab Biosimilar Market Attractiveness Analysis 12.26.1. By Product 12.26.2. By Distribution Channel 12.27. PEST Analysis 12.28. Key Trends 12.29. Key Developments 13. Middle East & Africa Adalimumab Biosimilar Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Adalimumab Biosimilar Market Overview 13.3. Middle East & Africa Adalimumab Biosimilar Market Value Share Analysis, By Product 13.4. Middle East & Africa Adalimumab Biosimilar Market Forecast, By Product 13.4.1. Exemptia 13.4.2. Adalirel 13.4.3. Cipleumab 13.4.4. Others 13.5. Middle East & Africa Adalimumab Biosimilar Market Value Share Analysis, By Distribution Channel 13.6. Middle East & Africa Adalimumab Biosimilar Market Forecast, By Distribution Channel 13.6.1. Hospitals Pharmacies 13.6.2. Retail Pharmacies 13.6.3. Others 13.7. Middle East & Africa Adalimumab Biosimilar Market Value Share Analysis, by Country 13.8. Middle East & Africa Adalimumab Biosimilar Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.9. Middle East & Africa Adalimumab Biosimilar Market Analysis, by Country 13.10. GCC Adalimumab Biosimilar Market Forecast, By Product 13.10.1. Exemptia 13.10.2. Adalirel 13.10.3. Cipleumab 13.10.4. Others 13.11. GCC Adalimumab Biosimilar Market Forecast, By Distribution Channel 13.11.1. Hospitals Pharmacies 13.11.2. Retail Pharmacies 13.11.3. Others 13.12. South Africa Adalimumab Biosimilar Market Forecast, By Product 13.12.1. Exemptia 13.12.2. Adalirel 13.12.3. Cipleumab 13.12.4. Others 13.13. South Africa Adalimumab Biosimilar Market Forecast, By Distribution Channel 13.13.1. Hospitals Pharmacies 13.13.2. Retail Pharmacies 13.13.3. Others 13.14. Nigeria Adalimumab Biosimilar Market Forecast, By Product 13.14.1. Exemptia 13.14.2. Adalirel 13.14.3. Cipleumab 13.14.4. Others 13.15. Nigeria Adalimumab Biosimilar Market Forecast, By Distribution Channel 13.15.1. Hospitals Pharmacies 13.15.2. Retail Pharmacies 13.15.3. Others 13.16. Egypt Adalimumab Biosimilar Market Forecast, By Product 13.16.1. Exemptia 13.16.2. Adalirel 13.16.3. Cipleumab 13.16.4. Others 13.17. Egypt Adalimumab Biosimilar Market Forecast, By Distribution Channel 13.17.1. Hospitals Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Others 13.18. Middle East & Africa Adalimumab Biosimilar Market Attractiveness Analysis 13.18.1. By Product 13.18.2. By Distribution Channel 13.19. PEST Analysis 13.20. Key Trends 13.21. Key Developments 14. South America Adalimumab Biosimilar Market Analysis 14.1. Key Findings 14.2. South America Adalimumab Biosimilar Market Overview 14.3. South America Adalimumab Biosimilar Market Value Share Analysis, By Product 14.4. South America Adalimumab Biosimilar Market Forecast, By Product 14.4.1. Exemptia 14.4.2. Adalirel 14.4.3. Cipleumab 14.4.4. Others 14.5. South America Adalimumab Biosimilar Market Value Share Analysis, By Distribution Channel 14.6. South America Adalimumab Biosimilar Market Forecast, By Distribution Channel 14.6.1. Hospitals Pharmacies 14.6.2. Retail Pharmacies 14.6.3. Others 14.7. South America Adalimumab Biosimilar Market Value Share Analysis, by Country 14.8. South America Adalimumab Biosimilar Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Argentina 14.9. South America Adalimumab Biosimilar Market Analysis, by Country 14.10. Brazil Adalimumab Biosimilar Market Forecast, By Product 14.10.1. Exemptia 14.10.2. Adalirel 14.10.3. Cipleumab 14.10.4. Others 14.11. Brazil Adalimumab Biosimilar Market Forecast, By Distribution Channel 14.11.1. Hospitals Pharmacies 14.11.2. Retail Pharmacies 14.11.3. Others 14.12. Mexico Adalimumab Biosimilar Market Forecast, By Product 14.12.1. Exemptia 14.12.2. Adalirel 14.12.3. Cipleumab 14.12.4. Others 14.13. Mexico Adalimumab Biosimilar Market Forecast, By Distribution Channel 14.13.1. Hospitals Pharmacies 14.13.2. Retail Pharmacies 14.13.3. Others 14.14. Argentina Adalimumab Biosimilar Market Forecast, By Product 14.14.1. Exemptia 14.14.2. Adalirel 14.14.3. Cipleumab 14.14.4. Others 14.15. Argentina Adalimumab Biosimilar Market Forecast, By Distribution Channel 14.15.1. Hospitals Pharmacies 14.15.2. Retail Pharmacies 14.15.3. Others 14.16. South America Adalimumab Biosimilar Market Attractiveness Analysis 14.16.1. By Product 14.16.2. By Distribution Channel 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Alfred E. Tiefenbacher (GmbH & Co. KG) 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Amgen Inc. 15.3.3. Boehringer Ingelheim International GmbH 15.3.4. Glenmark 15.3.5. Zydus Cadila 15.3.6. Torrent Pharmaceuticals Ltd. 15.3.7. Reliance Life Sciences 15.3.8. Emcure Pharmaceuticals Ltd 15.3.9. Cipla Inc. 15.3.10. Hetero 15.3.11. Others 16. Primary Key Insights